Revolution Medicines to Participate in Upcoming Investor Conferences
08 Junho 2023 - 5:05PM
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage
oncology company developing targeted therapies for RAS-addicted
cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the
company’s chief executive officer and chairman, will be a featured
speaker at the Goldman Sachs 44th Annual Global Healthcare
Conference and in Barclays’ ongoing series of virtual lunchtime
fireside chats.
Details of the company’s participation are as
follows:
- Goldman Sachs
44th Annual Global Healthcare
Conference Conference Dates: June 12-15, 2023Fireside Chat
Time/Date: 11:40 a.m. Eastern on Wednesday, June 14, 2023Location:
Dana Point, California; webcast available
- Barclays Virtual Fireside
Chat SeriesFireside Chat Time/Date: 12:00 p.m. Eastern on
Thursday, June 15, 2023Location: Virtual; webcast available
To access the live webcasts of the Goldman Sachs
and Barclays fireside chats, please visit the “Events &
Presentations” page of Revolution Medicines’ website at
https://ir.revmed.com/events-and-presentations. Additionally, a
replay of each webcast will be available on the “Events &
Presentations” page of the Revolution Medicines website for at
least 14 days following the conference.
About Revolution Medicines,
Inc.
Revolution Medicines is a clinical-stage
oncology company developing novel targeted therapies for
RAS-addicted cancers. The company’s R&D pipeline comprises
RAS(ON) Inhibitors designed to suppress diverse oncogenic variants
of RAS proteins, and RAS Companion Inhibitors for use in
combination treatment strategies. The company’s RAS(ON) Inhibitors
RMC-6236 (RASMULTI) and RMC-6291(KRASG12C) are currently in
clinical development. Additional RAS(ON) Inhibitors in the
company’s pipeline include RMC-9805 (KRASG12D) and RMC-0708
(KRASQ61H), both of which are currently in IND-enabling
development, RMC-8839 (KRASG13C), and additional compounds
targeting other RAS variants. RAS Companion Inhibitors in clinical
development include RMC-4630 (SHP2) and RMC-5552
(mTORC1/4EBP1).
Investors & Media Contact:
Erin Graves
650-779-0136
egraves@revmed.com
Revolution Medicines (NASDAQ:RVMD)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Revolution Medicines (NASDAQ:RVMD)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024